发明名称 |
Combinations for HCV Treatment |
摘要 |
The present invention relates to co-administering a Hepatitis C virus NS3/4A protease inhibitor and a cytochrome P450 monooxygenase inhibitor. The combination acts by interfering with the life cycle of the hepatitis C virus and is therefore useful as an antiviral therapy. As such, the combination may be used for treating or preventing Hepatitis C infections in patients. The invention also relates to compositions comprising the combination of inhibitors. The invention also relates to kits and pharmaceutical packs comprising a Hepatitis C virus NS3/4A protease inhibitor and a cytochrome P450 monooxygenase inhibitor. The invention also relates to processes for preparing these compositions, combinations, kits, and packs.
|
申请公布号 |
US2012114604(A1) |
申请公布日期 |
2012.05.10 |
申请号 |
US201213355638 |
申请日期 |
2012.01.23 |
申请人 |
TUNG ROGER;CHANDORKAR GURUDATT;PERNI ROBERT;VERTEX PHARMACEUTICALS INCORPORATED |
发明人 |
TUNG ROGER;CHANDORKAR GURUDATT;PERNI ROBERT |
分类号 |
A61K38/21;A61K31/13;A61K31/415;A61K31/426;A61K31/496;A61K31/7048;A61K31/7056;A61K31/7072;A61K38/05;A61K38/07;A61K38/13;A61K38/22;A61K45/00;A61K45/06;A61P31/14;A61P37/04 |
主分类号 |
A61K38/21 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|